Childhood retinal dystrophies are highly heterogeneous

Article

A study published in the British Journal of Ophthalmology has defined the heterogenous nature of retinal disorders.

A study published in the British Journal of Ophthalmology has defined the heterogeneous nature of retinal disorders.

Professor Jungoo S. Rahi et al., MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, London, UK, conducted a prospective, cross-sectional study on children with hereditary retinal disorders. Clinical and socio-demographic data was gathered on all patients at point of diagnosis and 9 months after using standardised questionnaires.

Of the children studied, 241 presented with 24 individual diagnoses, 14% had further systematic disorders and 13% had dual sensory impairment. The most frequent occurring mode of inheritance was autosomal recessive. It was found that hereditary conditions were most common in males, Asians and those living in socio-economic deprivation.

The findings have provided information on disease incidence, distributions and management. The results of the study can be used to develop novel therapies and to plan potential treatment programs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.